Clovis Oncology Now Covered by Leerink Swann (CLVS)
Investment analysts at Leerink Swann started coverage on shares of Clovis Oncology (NASDAQ:CLVS) in a note issued to investors on Friday. The firm set an “outperform” rating and a $100.00 price target on the stock. Leerink Swann’s price target would suggest a potential upside of 144.62% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Stifel Nicolaus upgraded shares of Clovis Oncology from a “hold” rating to a “buy” rating in a research note on Thursday, June 5th. They now have a $50.00 price target on the stock. Separately, analysts at Goldman Sachs cut their price target on shares of Clovis Oncology from $85.00 to $50.00 in a research note on Wednesday, June 4th. They now have a “neutral” rating on the stock. Finally, analysts at Citigroup Inc. downgraded shares of Clovis Oncology from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 3rd. They now have a $53.00 price target on the stock, down previously from $109.00. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Clovis Oncology has an average rating of “Buy” and a consensus price target of $74.13.
Clovis Oncology (NASDAQ:CLVS) opened at 40.88 on Friday. Clovis Oncology has a one year low of $35.33 and a one year high of $93.33. The stock has a 50-day moving average of $38.91 and a 200-day moving average of $56.93. The company’s market cap is $1.386 billion. Clovis Oncology also was the recipient of some unusual options trading on Friday. Stock investors bought 2,308 call options on the stock. This represents an increase of approximately 368% compared to the average daily volume of 493 call options.
Clovis Oncology (NASDAQ:CLVS) last released its earnings data on Thursday, August 7th. The company reported ($1.03) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.96) by $0.07. The company had revenue of $13.60 million for the quarter. During the same quarter last year, the company posted ($0.72) earnings per share. Analysts expect that Clovis Oncology will post $-3.85 EPS for the current fiscal year.
Clovis Oncology, Inc (NASDAQ:CLVS) is a Development-stage Company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.